This database contains 370 studies, archived under the term: "treatment outcome"
Click here to filter this large number of results.
The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer’s disease: a randomised controlled study
de Waal, Hanneke,
Stam, Cornelis J.,
Lansbergen, Marieke M.,
Wieggers, Rico L.,
Kamphuis, Patrick J. G. H.,
Scheltens, Philip,
Maestú, Fernando,
van Straaten, Elisabeth C. W.
Background: Synaptic loss is a major hallmark of Alzheimer’s disease (AD). Disturbed organisation of large-scale functional brain networks in AD might reflect synaptic loss and disrupted neuronal communication. The medical food Souvenaid, containing the specific nutrient combination Fortasyn Connect, is designed to enhance synapse formation and function and has been shown to improve memory performance […]
Silicon-rich mineral water as a non-invasive test of the ‘aluminum hypothesis’ in Alzheimer’s disease
Davenward, Samantha,
Bentham, Peter,
Wright, Jan,
Crome, Peter,
Job, Deborah,
Polwart, Anthony,
Exley, Christopher
There has been a plausible link between human exposure to aluminum and Alzheimer’s disease for several decades. We contend that the only direct and ethically acceptable experimental test of the ‘aluminum hypothesis’, which would provide unequivocal data specific to the link, is to test the null hypothesis that a reduction in the body burden of […]
Neuromidin in mixed vascular and Alzheimer’s dementia
The efficacy of neuromidin (ipidacrinum), a nonselective inhibitor of acetylcholinesterase and butyrilcholinesterase was studied in patients with mixed vascular and Alzheimer’s dementia of mild and moderate severity. Thirty patients of the main group received neyromidin in dosage 80 mg/day during 3 months; 10 patients of the comparison group matched by age, sex and severity of […]
Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer’s disease: a multicenter, randomized, open-label, parallel-group study
Choi, Seong Hye,
Park, Kyung Won,
Na, Duk L.,
Han, Hyun Jeong,
Kim, Eun-Joo,
Shim, Yong S.,
Lee, Jae-Hong,
The EXPECT Study Group,
Objective: To compare the tolerability and efficacy of combination therapy of memantine plus rivastigmine patch with rivastigmine patch monotherapy in patients with mild to moderate Alzheimer’s disease (AD).; Research Design and Methods: In this multicenter, randomized, open-label study, patients entered an 8-week run-in period (a 5 cm 2 rivastigmine patch for 4 weeks, then a […]
Continuous use of antipsychotics and its association with mortality and hospitalization in institutionalized Chinese older adults: an 18-month prospective cohort study
Chan, Tuen-Ching,
Luk, James Ka-Hay,
Shea, Yat-Fung,
Lau, Ka-Hin,
Chan, Felix Hon-Wai,
Yu, Gabriel Ka-Kui,
Chu, Leung-Wing
Background: Previous meta-analyses have suggested that antipsychotics are associated with increased mortality in dementia patients with behavioral and psychological symptoms (BPSD). Subsequent observational studies, however, have produced conflicting results. In view of this controversy and the lack of any suitable pharmacological alternative for BPSD, this study aimed to investigate the relationship between continuous use of […]
Safety and effectiveness of donepezil on behavioral symptoms in patients with Alzheimer disease
The objective of this study was to evaluate the prevalence and treatment responsiveness of neuropsychiatric symptoms in patients with mild to moderately severe Alzheimer disease recruited in a naturalistic treatment setting in Spain. All the patients, who matched the prescribing recommendations for donepezil and were able to participate in the study, received donepezil (5 to […]
Evidence for neurocognitive plasticity in at-risk older adults: the experience corps program
Carlson, M. C.,
Erickson, K. I.,
Kramer, A. F.,
Voss, M. W.,
Bolea, N.,
Mielke, M.,
McGill, S.,
Rebok, G. W.,
Seeman, T.,
Fried, L. P.
Objective: To determine whether Experience Corps (EC), a social service program, would improve age-vulnerable executive functions and increase activity in brain regions in a high-risk group through increased cognitive and physical activity.; Methods: Eight community-dwelling, older female volunteers and nine matched wait-list controls were recruited to serve in the ongoing EC: Baltimore program in three […]
Results of the citalopram to enhance cognition in Huntington disease trial
Beglinger, Leigh J.,
Adams, William H.,
Langbehn, Douglas,
Fiedorowicz, Jess G.,
Jorge, Ricardo,
Biglan, Kevin,
Caviness, John,
Olson, Blair,
Robinson, Robert G.,
Kieburtz, Karl,
Paulsen, Jane S.
Background: The objective of this study was to evaluate citalopram for executive functioning in Huntington’s disease (HD).; Methods: The study was randomized, double-blind, and placebo-controlled. Thirty-three adults with HD, cognitive complaints, and no depression (Hamilton Depression [HAM-D] rating scale ≤ 12) were administered citalopram 20 mg or placebo (7 visits, 20 weeks), with practice and […]